Stockscreener 앱 받기
19.05
6.07%
-1.39
Greenwich Lifesciences Inc 주식(GLSI)의 최신 뉴스
GLSIGreenwich LifeSciences Inc Latest SEC Filings - Finviz
GREENWICH LIFESCIENCES INC (GLSI) Stock Chart - ChartMill
Greenwich LifeSciences, Inc. Financial Disclosures & SEC Filings - TradingView
Price to book forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily
Greenwich LifeSciences, Inc. Actuals & Estimates (NASDAQ:GLSI) - TradingView
GLSI Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Price to sales forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Price to earnings forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Greenwich Lifesciences Inc (GLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GLSI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLSI Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - newsline.com
Technical Reactions to GLSI Trends in Macro Strategies - Stock Traders Daily
Greenwich LifeSciences (GLSI) Rises 4.47% as Shares Approach $25 ResistanceTechnical Analysis Picks - newsline.com
Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights - Minichart
Trading the Move, Not the Narrative: (GLSI) Edition - Stock Traders Daily
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Greenwich LifeSciences (GLSI) loss widens as ATM equity raises fund trials - Stock Titan
What’s Driving GLSI Stock Today? - Stocktwits
Noble Financial Reaffirms Their Buy Rating on Greenwich LifeSciences (GLSI) - The Globe and Mail
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Greenwich LifeSciences, Inc. 2024 Annual Report: Breast Cancer Immunotherapy Pipeline, Clinical Trials, and Regulatory Risks - minichart.com.sg
GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings - Quiver Quantitative
Greenwich LifeSciences FY 2025: Net loss $19.4M, No revenue — 10-K Summary - TradingView
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Greenwich LifeSciences delays 10-K filing, cites audit coordination By Investing.com - Investing.com Nigeria
Greenwich LifeSciences presents immune response data at ASCO - Investing.com
Greenwich LifeSciences presents immune response data at ASCO By Investing.com - Investing.com South Africa
Breast cancer trial: GLSI-100 shots spark injection-site reactions over time - Stock Titan
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial - TradingView
Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval - Moomoo
Greenwich Lifesciences Provides Update Regarding Form 10-K Filing - TradingView
Greenwich LifeSciences updates on Form 10-K filing progress - Traders Union
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Greenwich LifeSciences, Inc. Provides Update on 2025 Form 10-K Filing and Phase III Clinical Trial Progress - Quiver Quantitative
Greenwich LifeSciences delays 10-K filing, cites audit coordination - Investing.com
Breast cancer trial firm details audit delay, $10.5M cash - Stock Titan
Auddia’s Discovr Radio Forms AI-Driven Partnership With Beatcave to Expand Independent Artist Discovery Across Canada - Weekly Voice
Greenwich LifeSciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Greenwich LifeSciences (GLSI) Drops Nearly 10%: Key Support and Resistance Levels in FocusInsider Selling Alerts - The Legal Advocate
GLSI Q3 2025 Earnings: Narrower-than-Expected Loss as Biotech Advances Clinical PipelineLow Growth Earnings - newsline.com
Greenwich LifeSciences (GLSI) Slips Marginally as Stock Holds Above Key SupportIchimoku Kumo Twist - The Legal Advocate
Greenwich LifeSciences Inc. (GLSI) Q3 2025 Earnings: Narrowed Loss Highlights Progress in Immunotherapy DevelopmentQuarterly Earnings - newsline.com
Greenwich LifeSciences (GLSI) Inches Higher Amid Calm Trading SessionBeta Neutral Pair - dars.gov.et
Greenwich LifeSciences (GLSI) Slips 0.94% as Stock Hovers Near Key SupportLow Risk Entry Stocks - dars.gov.et
1.21%
3.14%
자본화:
|
볼륨(24시간):